Study shows benefit of the first AI-supported functional precision medicine platform to guide treatment selection and improve outcomes in patients with advanced haematological cancers 54% of patients
Buch über die Bewältigung von Krisen tips.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tips.at Daily Mail and Mail on Sunday newspapers.
PRESS RELEASE : Apogenix AG: COVID-19 targeted treatment trial launched in Vienna marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
DGAP-News: Apogenix AG / Key word(s): Study
22.12.2020 / 10:00
COVID-19: targeted treatment trial launched in Vienna
(Vienna/Heidelberg/Cologne/London, 22 December 2020) A phase II clinical trial of a treatment for COVID-19 patients is currently starting at the Medical University of Vienna as a sub-study of the Austrian CoronaVirus Adaptive Clinical Trial (ACOVACT). The trial was initiated as an academia-industry collaboration (investigator Initiated trial) between Apogenix AG, a biotech company based in Heidelberg, and their scientific consultant Henning Walczak and his teams at the University of Cologne and University College London (UCL).
Patients with severe to critical COVID-19 are now being treated with an immunotherapeutic drug, the Fas ligand blocker asunercept, from Apogenix within the framework of the Austrian CoronaVirus Adaptive Clinical Trial (ACOVACT). ACOVACT is a randomised, controlled, multi-centre, open-label clinical trial sponsored by MedUni Vienna. Within